trending Market Intelligence /marketintelligence/en/news-insights/trending/i--nm_0pG_UFKRiYEhMnug2 content esgSubNav
In This List

AstraZeneca's Farxiga cuts risk of sudden death in heart failure patients

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


AstraZeneca's Farxiga cuts risk of sudden death in heart failure patients

AstraZeneca PLC said its drug Farxiga significantly cut the risk of heart-related sudden death or worsening of disease in certain heart failure patients, according to data from a late-stage study.

Statistically significant and clinically meaningful results from the phase 3 clinical trial, dubbed DAPA-HF, showed Farxiga, or dapagliflozin, reduced cardiovascular death or hospital admission in certain patients with heart failure, including those with and without type 2 diabetes — meeting the study's main composite goal.

Patients assessed in the study had heart failure, a condition in which the heart does not have the capacity to pump enough blood to maintain blood flow in a person's body. These patients also had reduced ejection fraction, in which the muscle of the left ventricle is not pumping normally, and had standard of care treatment.

The Cambridge, U.K.-based drugmaker will submit full results of the DAPA-HF study for presentation at a forthcoming medical meeting.

Farxiga, which is marketed as Forxiga in the EU, is also being evaluated in patients with heart failure with preserved ejection fraction —the heart muscle pumps normally but is too stiff to fill properly with blood — in clinical trials named Deliver and Determine.